Vaxcyte Advances VAX-31 Toward Phase 3 As Valuation Gap Persists [Yahoo! Finance]
Vaxcyte, Inc. (PCVX)
Company Research
Source: Yahoo! Finance
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Vaxcyte (NasdaqGS:PCVX) reported unprecedented Phase 2 results in adults for its 31-valent pneumococcal vaccine candidate, VAX-31. The company is moving rapidly into multiple Phase 3 trials following the positive Phase 2 data. A large-scale manufacturing facility has been completed to support potential future commercial supply. Vaxcyte has appointed a new Chief Commercial Officer as it prepares for possible global commercialization. For investors watching Vaxcyte at a share price of $61.74, these clinical and operational updates come after a mixed share price record, with a 32.9% return year to date and a 152.2% return over 5 years, alongside a 14.4% decline over the past year. The company is moving further along the vaccine development path, and the current data and corporate moves give investors more information to weigh around its progress. The transition toward
Show less
Read more
Impact Snapshot
Event Time:
PCVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCVX alerts
High impacting Vaxcyte, Inc. news events
Weekly update
A roundup of the hottest topics
PCVX
News
- Does Heavy 2025 Loss and Large Equity Raise for Vaxcyte's VAX-31 Shift the Bull Case (PCVX)? [Yahoo! Finance]Yahoo! Finance
- Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock. [Yahoo! Finance]Yahoo! Finance
- A Look At Vaxcyte (PCVX) Valuation As Share Price Momentum Rebuilds [Yahoo! Finance]Yahoo! Finance
- Vaxcyte, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Vaxcyte (PCVX) had its "buy" rating reaffirmed by BTIG Research.MarketBeat
PCVX
Earnings
- 2/24/26 - Miss
PCVX
Sec Filings
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- PCVX's page on the SEC website